Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series

Obesity is highly prevalent and comes with serious health burden. In a minority, a genetic cause is present which often results in therapy‐resistant obesity. Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue, which has beneficial effects on satiety and weight in common obesity. We present the effects of GLP‐1 analogues in adults with a molecularly proven genetic cause of their overweight or obesity. All patients were treated with liraglutide 3.0 mg daily, in addition to intensive supportive lifestyle treatment. Anthropometrics, metabolic parameters, resting energy expenditure (REE), side effects, and subjectively reported satiety and quality of life were assessed. Two patients with 16p11.2 deletion syndrome and two patients with heterozygous pathogenic melanocortin‐4 receptor variants were treated. At baseline, their age ranged between 21 and 32 years and body mass index (BMI) ranged between 28.1 and 55.7 kg/m(2). At follow‐up (ranges 43 weeks–12 years), a mean change in BMI and waist circumference was observed of −5.7 ± 3.8 kg/m(2) and −15.2 ± 21.1 cm, respectively. All patients achieved ≥5% weight loss, three of them lost ≥10% of their body weight. All patients reported improved quality of life and three of them reported ameliorated satiety. Moreover, improvement of glycaemic control and dyslipidaemia were seen. In two patients, REE before and during treatment was measured, which either increased (+26% of predicted REE) or decreased (−18% of predicted REE). Two patients experienced mild side effects for a brief period. In conclusion, our case series shows beneficial effects of GLP‐1 analogues on weight, metabolic parameters and quality of life in all four patients with genetic obesity.